[Bone metabolism in 53 children and adolescents with chronic inflammatory bowel disease].
BACKGROUND
Osteopathy is a common clinical feature of chronic inflammatory bowel disease (IBD) in children and young adults at the time of primary diagnosis. The aim of the following study was to address the question of prevalance of a decreased bone density or increased bone metabolism in children with IBD.


METHODS
We examined 63 patients (mean age 13 years; 5 - 18 years): 36 Crohn's disease (MC) patients, 16 colitis ulcerosa (CU) patient and one patient with colitis indeterminata (CID). 10 children who had been referred to the gastroenterological outpatient department due to suspected IBD symptoms were later found not to suffer from IBD. These 10 patients therefore were included in the study as controls.


RESULTS
8 of 10 CU patients and 18 of 28 MC patients showed a pathological bone density and abnormalities in bone metabolism. Repetitive bone density measurement was performed in 18 patients. In MC patients a - 0.39 SDS decrease of bone mineral density was found, without a simultaneous deterioration of clinical stage and inspite of a decreased cumulative prednisolon dosage. However in CU patients a + 0.06 SDS increase of bone mineral density was detected. These patients had a lower cumulative prednisolon dosage and a stable clinical course.


CONCLUSIONS
In conclusion, pediatric IBD patients often show abnormalities in bone metabolism and decreased bone density. There is a need for multicentre, prospective randomised control trials to further identify therapeutic tools on the basis of the multifactorial etiology of bone disease in pediatric IBD patients.
Scheer
K
K
Universitätsklinik und Poliklinik für Kinder und Jugendliche, Leipzig.
Kratzsch
J
J
Deutscher
J
J
Gelbrich
G
G
Borte
G
G
Kiess
W
W
D015502:Absorptiometry, Photon; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D001851:Bone Diseases, Metabolic / Q000139:chemically induced / Q000175:diagnosis*; D002648:Child; D002675:Child, Preschool; D003093:Colitis, Ulcerative / Q000175:diagnosis* / Q000188:drug therapy; D003424:Crohn Disease / Q000175:diagnosis* / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000175:diagnosis*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012016:Reference Values; D012307:Risk Factors
D000893:Anti-Inflammatory Agents; D011241:Prednisone